Arlington Medical Resources (AMR) and BioTrends Research Group find that less than half of surveyed infectious disease (ID) specialists and only 6 percent of surveyed internists demonstrated unaided awareness of and familiarity with Dificid prior to its U.S. launch in mid-July. In LaunchTrends®Institutional: Dificid, AMR and BioTrends surveyed 100 U.S. ID specialists and internists about their current treatment practices for C. difficile infection (CDI) as well as their awareness, perceptions, and anticipated future use of Dificid.
Dificids sustained clinical response rate at 25 days following end of treatment is regarded by physicians as the drugs most significant advantage in the treatment of CDI. However, the cost of Dificid ($2,800 for a 10-day course) comes as a surprise to most surveyed physicians and is regarded as the most significant obstacle to the drugs use, including use in patients at hospital discharge and those in nursing home and long-term care facilities. Results from the study find that physicians are split regarding whether or not the cost of a 10-day course of Dificid outweighs its advantages.
"Early use of Dificid will likely be limited to patients with severe or severe/complicated disease and those experiencing recurrent, recalcitrant, or resistant infection," says AMRs vice president of research Danielle L. Drayton, PhD. "The cost of the drug is clearly seen by physicians as a barrier to use in the outpatient setting and in patients with their first episode of mild infection for which physicians prefer to begin treatment with less expensive and more established options."
The study also finds that oral vancomycin is the therapy most likely to be displaced by Dificid. However, the practice of compounding IV-based vancomycin for oral delivery will be a key barrier to Dificid replacement of vancomycin. Compounded IV-based vancomycin for oral delivery effectively represents generic vancomycin competition in the CDI market. Physicians report that use of IV-based vancomycin is common in their hospital and more often than not, their hospitals pharmacy automatically compounds IV vancomycin for oral delivery.
I Was There: An Infection Preventionist on the COVID-19 Pandemic
April 30th 2025Deep feelings run strong about the COVID-19 pandemic, and some beautiful art has come out of those emotions. Infection Control Today is proud to share this poem by Carmen Duke, MPH, CIC, in response to a recent article by Heather Stoltzfus, MPH, RN, CIC.
From the Derby to the Decontam Room: Leadership Lessons for Sterile Processing
April 27th 2025Elizabeth (Betty) Casey, MSN, RN, CNOR, CRCST, CHL, is the SVP of Operations and Chief Nursing Officer at Surgical Solutions in Overland, Kansas. This SPD leader reframes preparation, unpredictability, and teamwork by comparing surgical services to the Kentucky Derby to reenergize sterile processing professionals and inspire systemic change.
Show, Tell, Teach: Elevating EVS Training Through Cognitive Science and Performance Coaching
April 25th 2025Training EVS workers for hygiene excellence demands more than manuals—it requires active engagement, motor skills coaching, and teach-back techniques to reduce HAIs and improve patient outcomes.